What Is Digital Pathology?

Digital pathology involves digitising glass histology slides using whole slide imaging (WSI) scanners — capturing the entire slide at 20x or 40x magnification as a multi-gigapixel digital image file. These digital slides can then be:

• Viewed remotely by pathologists worldwide through telepathology platforms
• Analysed by AI algorithms for feature detection, cell counting, and prognostic scoring
• Stored long-term in digital archives replacing physical slide storage
• Used for education, training, and proficiency testing
• Integrated with laboratory information systems (LIS) and hospital information systems (HIS)

Market Size and Key Players

AI-Assisted Pathology — The Commercial Acceleration

AI diagnostic algorithms applied to digitised slides are demonstrating clinical utility that is accelerating hospital adoption:

• Paige Prostate (FDA-cleared): AI detection of prostate cancer in biopsies — demonstrated 7.3% increase in cancer detection and 70% reduction in pathologist review time for negative cases
• Aiforia Cervical AI: CE-marked AI cervical cytology analysis — automated screening with pathologist review of flagged cases
• Breast cancer HER2 scoring: AI-automated HER2 immunohistochemistry scoring has demonstrated higher consistency than manual scoring across multiple published studies
• Computational tumour microenvironment analysis: AI quantification of tumour-infiltrating lymphocytes (TILs) and spatial biomarkers — providing prognostic and predictive information beyond conventional pathology

AI-assisted pathology tools are IVD SaMD (Software as a Medical Device) — regulated under EU IVDR Class C or D in Europe, requiring Notified Body review.

Regulatory Status of Digital Pathology

• WSI scanners: Regulated as Class II medical devices (IVD) — CE Mark required; FDA 510(k) cleared for primary diagnosis (Philips IntelliSite cleared 2017, Leica AT2 cleared 2019)
• AI diagnostic algorithms: Regulated as IVD SaMD — EU IVDR Class C/D requiring NB review; FDA cleared several (Paige Prostate, Paige Lymph Node Metastasis) with more under review
• Teleconsultation platforms: If used for primary diagnosis (not just case review), regulated as medical devices in most jurisdictions
• IVDR transition relevance: AI pathology algorithms are Class C or D IVDR — manufacturers must complete IVDR certification by May 2027 (Class C) or May 2027 (Class D was May 2026)

Opportunities for Turkish Distributors and Manufacturers

• WSI scanner distribution: Turkish distributors with laboratory and pathology portfolios can add WSI scanner lines from 3DHISTECH (Hungarian manufacturer, competitive pricing, strong emerging market presence) or Hamamatsu — accessible technology with growing demand in Turkish and regional teaching hospitals
• Turkish pathology department digitisation: Turkey's university teaching hospitals (Hacettepe, Ege, İstanbul) and major private hospital groups are beginning WSI adoption — a domestic market opportunity for Turkish medical device distributors
• Middle East and Africa telepathology: Telepathology using digital platforms enables pathology expertise access in regions with specialist shortages — a technology access equity story that resonates with Gulf and African government procurement
• TÜBİTAK-funded AI pathology development: Turkish universities with AI research capability (İTÜ, METU AI labs) + medical device manufacturers = potential for Turkish-developed AI pathology SaMD — eligible for TÜBİTAK 1507 and Horizon Europe funding